To study the efficacy of Curcuma longa extract in Osteoarthritis of knee patients.

Evaluation of anti-oxidant and anti-inflammatory activity of Curcuma longa extract in osteoarthritis subjects: A pharmacological approach.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/12/006438

Enrollment

160

Registered

2015-12-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee Health Condition 2: null- Primary Osteoarthritis of knee

Interventions

Intervention1: Curcuma longa extract: Curcuma longa extract capsules (500 mg) BD along with Diclofenac 50 mg were given for four months. Control Intervention1: Extract of Curcuma longa: 500 mg BD Cont

Eligibility

Inclusion criteria

Inclusion criteria: Primary osteoarthritis of knee

Exclusion criteria

Exclusion criteria: Subject having RA and secondary arthritis. Subjects more than 80 years and less than 40 years. Subjects having metabolic disorder such as diabetes, hepatitis, cardiovascular disease. Subject having malignant disease. Subject having other genetic disorder. Subject having respiratory disease. Subject having HIV disease.

Design outcomes

Primary

Measure	Time frame
WOMAC score Visual Analog Scale serum uric acid,IL-1 beta, IL-10, MMP-9, Reactive Oxygen Species. Enzymes: SOD, CatalaseTimepoint: At base line, after two months and fourth month	—

Secondary

Measure	Time frame
WOMAC score Visual Analog Scale serum uric acid,IL-1 beta, IL-10, MMP-9, Reactive Oxygen Species. Enzymes: SOD, CatalaseTimepoint: At base line, after two months and fourth month	—

Countries

India

Contacts

Public ContactShobhit Srivastava

King Georges Medical University

saksenaa54@yahoo.co.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026